MoneyWorks4Me

Beryl Drugs - Quaterly Results

09 Aug 2022 Evaluate
The revenue zoomed 6.88% to Rs. 49.68 millions for the quarter ended June 2022 as compared to Rs. 46.48 millions during the corresponding quarter last year.The Net Profit of the company slipped to Rs. 2.17 millions from Rs. 3.39 millions, a decline of -35.99% on QoQ basis.A decline of 5.94 millions was observed in the OP in the quarter ended June 2022 from 7.08 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 49.68 46.48 6.88 49.68 46.48 6.88 147.69 142.80 3.42
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 5.94 7.08 -16.10 5.94 7.08 -16.10 5.73 16.36 -64.98
Interest 1.26 1.11 13.51 1.26 1.11 13.51 4.37 4.66 -6.22
PBDT 4.68 5.97 -21.61 4.68 5.97 -21.61 1.36 16.22 -91.62
Depreciation 2.47 2.99 -17.39 2.47 2.99 -17.39 10.86 12.73 -14.69
PBT 2.21 2.98 -25.84 2.21 2.98 -25.84 -9.50 3.49 -372.21
TAX 0.04 -0.41 -109.76 0.04 -0.41 -109.76 -2.91 1.08 -369.44
Deferred Tax 0.04 -0.41 -109.76 0.04 -0.41 -109.76 -3.00 1.08 -377.78
PAT 2.17 3.39 -35.99 2.17 3.39 -35.99 -6.59 2.41 -373.44
Equity 50.72 50.72 0.00 50.72 50.72 0.00 50.72 50.72 0.00
PBIDTM(%) 11.96 15.23 -21.51 11.96 15.23 -21.51 3.88 11.46 -66.13
Peers
Company Name CMP
Sun Pharma. Inds. 1847.00
Dr. Reddys Labs. 1212.30
Cipla 1368.65
Lupin 2121.05
Zydus Lifesciences 1170.00
View more..